A 'pre-induction course' with non-cross-reacting cytostatic drugs for rapid tumour load reduction improves outcome in adult acute lymphoblastic leukaemia.
Daenen
Simon
S
van Imhoff
Gustaaf W
GW
de Wolf
Joost T M
JT
Vellenga
Edo
E
van den Berg-de Ruiter
Eva
E
Kluin-Nelemans
Hanneke C
HC
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D016896:Treatment Outcome; D047368:Tumor Burden / Q000187:drug effects
D000970:Antineoplastic Agents; D003561:Cytarabine; D005047:Etoposide; D008727:Methotrexate